Meridian Bioscience Inc. Stock
Your prediction
Meridian Bioscience Inc. Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Meridian Bioscience Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Meridian Bioscience Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Meridian Bioscience Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Meridian Bioscience Inc. | - | - | - | - | - | - | - |
| SI-BONE Inc | 0.890% | 2.727% | -15.672% | -14.394% | -33.136% | - | - |
| Lantheus Holdings Inc | -0.550% | -0.362% | 1.134% | -26.481% | 15.420% | -13.699% | - |
| Orasure Tech | 1.530% | 1.527% | 6.400% | -13.072% | 29.126% | -49.811% | -73.006% |
News
Atlas Energy Stock Jumps 39% YTD, but One Fund Cut Exposure by $15 Million Last Quarter
On February 17, 2026, Meridian Wealth Advisors disclosed a reduction in its Atlas Energy Solutions (NYSE:AESI) position, selling 1,458,193 shares for an estimated $14.74 million based on average
This REIT Is Down 60% Since 2006, but a $9.2 Million Bet Says There’s Still Value
New York City-based DSC Meridian Capital initiated a new position in Elme Communities (NYSE:ELME), acquiring 543,081 shares valued at approximately $9.2 million, according to a November 14 SEC
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year
New York City-based DSC Meridian Capital fully exited its position in Bausch + Lomb during the third quarter, reducing its holdings by 510,090 shares, a move totaling approximately $6.6 million.